: The currently available clinical anticancer approaches pertaining to the treatment of prostate cancer are summarized here. After providing an overview of the main features of this highly impactful global disease, the currently available clinical treatments are briefly reviewed. Then, alternative and innovative nano-based therapeutic options that have been proposed or are currently being explored to significantly improve prostate cancer management (i.e. anti-prostate cancer polymeric nanoparticles loaded with drugs to promote their release and biological activity, including non-targeted and functionalized PLGA-PEG NPs and AuNPs), are introduced. Furthermore, the problem of gathering insights into the mechanistic aspects related to the fate of the nanoformulation in complex matrices, such as blood plasma, is addressed.

From conventional therapy to novel nano-based approaches. A focus on prostate cancer

Chiaverini, Lorenzo
Primo
Writing – Original Draft Preparation
;
Di Leo, Riccardo
Writing – Original Draft Preparation
;
Barresi, Elisabetta
Writing – Review & Editing
;
La Mendola, Diego
Writing – Review & Editing
;
Bartoli, Francesco
Writing – Review & Editing
;
Famlonga, Luca
Membro del Collaboration Group
;
Faviana, Pinuccia
Writing – Review & Editing
;
Zucchi, Alessandro
Membro del Collaboration Group
;
Pacini, Matteo
Membro del Collaboration Group
;
Giacomelli, Chiara
Penultimo
Writing – Review & Editing
;
Marzo, Tiziano
Ultimo
Conceptualization
2025-01-01

Abstract

: The currently available clinical anticancer approaches pertaining to the treatment of prostate cancer are summarized here. After providing an overview of the main features of this highly impactful global disease, the currently available clinical treatments are briefly reviewed. Then, alternative and innovative nano-based therapeutic options that have been proposed or are currently being explored to significantly improve prostate cancer management (i.e. anti-prostate cancer polymeric nanoparticles loaded with drugs to promote their release and biological activity, including non-targeted and functionalized PLGA-PEG NPs and AuNPs), are introduced. Furthermore, the problem of gathering insights into the mechanistic aspects related to the fate of the nanoformulation in complex matrices, such as blood plasma, is addressed.
2025
Chiaverini, Lorenzo; Ferraro, Giarita; Di Leo, Riccardo; Barresi, Elisabetta; La Mendola, Diego; Bartoli, Francesco; Famlonga, Luca; Satriano, Cristin...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1310507
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact